Previous 10 | Next 10 |
Baker Brothers’ 13F portfolio value decreased from $26.54B to $23.07B this quarter. The large stake in Alexion Pharmaceuticals was decreased during the quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~57% of the portfol...
Shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP) traded at a new 52-week low today of $3.68. Approximately 263,000 shares have changed hands today, as compared to an average 30-day volume of 1.1 million shares. There is potential upside of 5.5% for shares of Adaptimmune Therapeutics ...
Dogecoin (CRYPTO: DOGE) , in many ways, is at the epicenter of the cryptocurrency craze. Its price appreciated by a staggering 12,000% during just the first five months of 2021. The probability that this star of the cryptocurrency world will keep churning higher, however, appears to...
I covered Adaptimmune in December. This article covers all that has changed since then. A BLA filing next year could be a major catalyst. For further details see: Adaptimmune Therapeutics: Still The TCR Leader, And With Major Upcoming Catalysts
ASCO is a very important cancer clinical research meeting. We identified 70 smid-cap cancer companies presenting updated clinical data at ASCO21. 13 companies' value increased by over 10% with ASCO21 info release thus far. PDSB is an early ASCO21 mover, with its HPV vaccine ca...
Seeing a bigger upside from overweight-rated stocks in its coverage, Barclays has initiated Adaptimmune Therapeutics ([[ADAP]] -2.0%) with an underweight recommendation.The price target of $4.00 per share indicates a downside of ~20.8% to the previous close. After two consecutive days of gain...
Adaptimmune Therapeutics (NASDAQ: ADAP) , a biotech company active in the hot immunotherapy segment, was a high-temperature stock on Thursday. Following the release of detailed phase 2 clinical trial results for a promising cancer treatment, the company's shares rose by nearly 4.5% ...
Adaptimmune Therapeutics shares rise ([[ADAP]] +4.9%) as the company talked up initial data from its mid-stage afamitresgene autoleucel cancer trial ahead of its presentation at the upcoming American Society of Clinical Oncology ((ASCO)) congress.At the time of data cut-off, 37 patients had r...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Welcome back once again, investors, and let’s get ready for a busy day of trading! We’re kicking off the day with a look at the biggest pre-market stock movers for Thursday below. Source: oneinchpunch/Shut...
- Data will support BLA filing for afamitresgene autoleucel next year - - Responses observed across a broad range of antigen expression - - Initial safety and durability are encouraging - PHILADELPHIA and OXFORDSHIRE, United Kingdom, May 19, 2021 (GLOBE NEWSWIRE) -- Adaptimmun...
News, Short Squeeze, Breakout and More Instantly...
Adaptimmune Therapeutics plc Company Name:
ADAP Stock Symbol:
NASDAQ Market:
Adaptimmune Therapeutics plc Website:
Overall response rate of 40% consistent across sarcoma indications; median duration of response ~11 months with patients still in response at time of analysis Interim analysis data reinforces the potential of lete-cel to bolster Adaptimmune's sarcoma franchise by expanding addressable sarcoma pa...
2024-05-31 16:15:02 ET Wells Fargo analyst issues EQUAL-WEIGHT recommendation for ADAP on May 31, 2024 02:43PM ET. The previous analyst recommendation was Equal-Weight. ADAP was trading at $1.135 at issue of the analyst recommendation. The overall analyst consensus : BUY...